Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Refractory Prostate Cancer Disease”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06084338
What this trial is testing

Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc

Who this might be right for
Prostate Cancer
VA Office of Research and Development 60
Testing effectiveness (Phase 2)Ended earlyNCT02758132
What this trial is testing

Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases

Who this might be right for
Prostate Cancer
University of Hawaii 1
Early research (Phase 1)Study completedNCT01085422
What this trial is testing

A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
AbbVie (prior sponsor, Abbott) 35
Very early researchStudy completedNCT03071328
What this trial is testing

INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers

Who this might be right for
Metastatic Castration-resistant Prostate Cancer (mCRPC)Metastatic Urothelial CarcinomaMetastatic Renal Cell Carcinoma
Duke University 10
Not applicableWithdrawnNCT02905201
What this trial is testing

A Prospective Compliance Registry for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostatic Neoplasms
Janssen Research & Development, LLC
Testing effectiveness (Phase 2)Ended earlyNCT05256381
What this trial is testing

SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors

Who this might be right for
Non-Small Cell Lung CancerColorectal CancerCutaneous Squamous Cell Carcinoma+3 more
SOTIO Biotech AG 166
Testing effectiveness (Phase 2)Study completedNCT00150995
What this trial is testing

Tetrathiomolybdate in Hormone Refractory Prostate Cancer

Who this might be right for
Prostate Cancer
University of Michigan Rogel Cancer Center 19
Testing effectiveness (Phase 2)Ended earlyNCT05075577
What this trial is testing

EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC

Who this might be right for
Prostate Cancer
ESSA Pharmaceuticals 77
Large-scale testing (Phase 3)Study completedNCT05547386
What this trial is testing

68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Castration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaStage IVB Prostate Cancer AJCC v8
Mayo Clinic 163
Early research (Phase 1)Study completedNCT03737370
What this trial is testing

Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castrate Resistant Prostate Cancer
Tufts Medical Center 43
Testing effectiveness (Phase 2)Ended earlyNCT03330405
What this trial is testing

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

Who this might be right for
Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
Pfizer 223
Large-scale testing (Phase 3)Study completedNCT01193257
What this trial is testing

Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer.

Who this might be right for
Prostate Cancer
Millennium Pharmaceuticals, Inc. 1,099
Testing effectiveness (Phase 2)WithdrawnNCT00242931
What this trial is testing

Flu/TBI in Treating Patients Not Responding to Previous Hormone Therapy

Who this might be right for
Prostate Cancer
OHSU Knight Cancer Institute
Testing effectiveness (Phase 2)Study completedNCT00003400
What this trial is testing

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
University of Maryland, Baltimore 45
Testing effectiveness (Phase 2)Study completedNCT00090545
What this trial is testing

A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer

Who this might be right for
Prostate Cancer
National Cancer Institute (NCI) 46
Testing effectiveness (Phase 2)Study completedNCT00193193
What this trial is testing

Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma

Who this might be right for
Prostate Cancer
SCRI Development Innovations, LLC 100
Testing effectiveness (Phase 2)Ended earlyNCT02565901
What this trial is testing

Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Castration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaStage IV Prostate Cancer AJCC v7+1 more
University of Washington 28
Testing effectiveness (Phase 2)Ended earlyNCT00176644
What this trial is testing

Phase II Trial of Transdermal Estradiol for Hormone Refractory Prostate Cancer

Who this might be right for
Prostate Cancer
University of Medicine and Dentistry of New Jersey 23
Early research (Phase 1)Study completedNCT01832870
What this trial is testing

Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer

Who this might be right for
Prostate CancerCastrate Resistant Prostate Cancer
Prostate Oncology Specialists, Inc. 9
Testing effectiveness (Phase 2)Study completedNCT00738673
What this trial is testing

Degarelix as Second-Line Hormonal Treatment After Prostate-specific Antigen (PSA)-Failure in GnRH Agonist Treated Patients With Prostate Cancer

Who this might be right for
Prostate Cancer
Ferring Pharmaceuticals 37
Next Page